uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
New frontiers in the management of arterial thrombosis with oral anticoagulants
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
2008 (English)In: Thrombosis and Haemostasis, ISSN 0340-6245, Vol. 100, no 6, A15-A19 p.Article in journal (Refereed) Published
Abstract [en]

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its prevalence increases substantially with age. As patients with AF have an almost five-fold greater risk of stroke than those without AF, stroke prevention in AF (SPAF) represents a key therapeutic goal. The current standard of therapy for SPAF involves treatment with a vitamin K antagonist or aspirin; however, these agents are associated with important limitations that restrict their uptake and effective use. There are currently intense efforts to develop a new, effective, and safe antithrombotic treatment for use in SPAF, with research focusing on oral direct thrombin inhibitors (DTIs; e.g. dabigatran etexilate) and factor Xa inhibitors (e.g. apixaban, rivaroxaban). Of these, the oral DTI, dabigatran etexilate, is the most advanced in clinical development. The phase II PETRO study and its long-term extension trial, PETRO-Ex, together formed the basis for the ongoing phase III RE-LY (TM) trial, which is comparing the efficacy of two blinded doses of dabigatran etexilate (110 mg bid and 150 mg bid) with that of open-label warfarin in SPAF for a treatment duration of up to three years. Results are expected in 2009. An ongoing phase 11 dose-finding, safety, and tolerability study (RE-DEEM (TM)) is also assessing dabigatran etexilate in the secondary prevention of cardiac events in post-index myocardial infarction patients. It is expected that the results of this trial will guide the selection of an appropriate dose for further clinical testing in this indication.

Place, publisher, year, edition, pages
2008. Vol. 100, no 6, A15-A19 p.
Keyword [en]
Anticoagulants, atrial fibrillation, dabigatran etexilate, stroke
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-152152ISI: 000261880900014OAI: oai:DiVA.org:uu-152152DiVA: diva2:412686
Available from: 2011-04-26 Created: 2011-04-26 Last updated: 2012-07-13Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Wallentin, Lars C.
By organisation
UCR-Uppsala Clinical Research CenterDepartment of Medical Sciences
In the same journal
Thrombosis and Haemostasis
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 171 hits
ReferencesLink to record
Permanent link

Direct link